Knights of Columbus Asset Advisors LLC Has $7.09 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Knights of Columbus Asset Advisors LLC lifted its position in Insmed Incorporated (NASDAQ:INSM) by 101.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 228,783 shares of the biopharmaceutical company’s stock after buying an additional 114,987 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Insmed were worth $7,090,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in INSM. International Assets Investment Management LLC acquired a new position in shares of Insmed during the 4th quarter worth about $25,000. Almanack Investment Partners LLC. bought a new position in shares of Insmed during the third quarter worth approximately $25,000. State of Wyoming acquired a new position in Insmed during the fourth quarter valued at approximately $31,000. RVW Wealth LLC acquired a new position in Insmed during the third quarter valued at approximately $53,000. Finally, Quantbot Technologies LP increased its holdings in shares of Insmed by 2,170.4% during the second quarter. Quantbot Technologies LP now owns 2,452 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 2,344 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have commented on INSM. Barclays upped their price target on shares of Insmed from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 11th. UBS Group initiated coverage on shares of Insmed in a research report on Tuesday, February 27th. They set a “buy” rating and a $46.00 target price for the company. Wells Fargo & Company reissued an “overweight” rating and issued a $55.00 price target on shares of Insmed in a report on Monday, April 1st. Wolfe Research assumed coverage on Insmed in a report on Thursday, February 15th. They set an “outperform” rating and a $42.00 target price for the company. Finally, StockNews.com upgraded Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.64.

Insmed Stock Down 2.6 %

Shares of INSM stock traded down $0.64 during mid-day trading on Friday, hitting $24.16. 1,371,560 shares of the stock were exchanged, compared to its average volume of 1,688,090. The firm has a fifty day moving average of $27.45 and a 200 day moving average of $27.02. Insmed Incorporated has a 52-week low of $17.41 and a 52-week high of $32.00. The company has a market cap of $3.59 billion, a PE ratio of -4.64 and a beta of 0.92.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The firm had revenue of $83.70 million for the quarter, compared to analyst estimates of $82.15 million. Insmed’s revenue was up 41.1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.20) EPS. Equities analysts predict that Insmed Incorporated will post -4.65 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.